TABLE 3 CALGB 9221: Responses to azacitidine in patients with myelodysplastic syndromes, according to FAB subtype 14
From the following article:
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
Lewis R Silverman and Ghulam J Mufti
BACK TO ARTICLE| Response | RA/RARS (n = 22) | RAEB/RAEBT/CMMoL (n = 66) |
|---|---|---|
CMMoL, chronic myelomonocytic leukemia; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEBT, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ringed sideroblasts. | ||
| Complete | 2 (9%) | 5 (8%) |
| Partial | 4 (18%) | 10 (15%) |
| Improved | 7 (32%) | 25 (38%) |
| Total | 13 (59%) | 40 (61%) |
